Abstract: A research commercialisation programme mapped the Slovak self-governing region of Bratislava for existing and potential spin-off companies. Identification and evaluation analyses of the technology transfer in biotechnology-oriented research were executed. Results of the study confirmed the quality of present level of science but a lack of commercialisation of professional services on the other hand. Financial plans for suggested spin-off business models were predicted by licensed BioBiz TM software programme.
Introduction
Technology transfer in biology-and biotechnologyoriented research is highly discussed topic since its beginnings in the early eighties in the past century (Boni 2011) . The traditional activities of technology transfer range from identification of research results from the university or research institution setting to their transfer to the market. The question is whether the public sector can be oriented to unblock some biotech research programs and reopen commercial avenues for those that are commercially supportable (Marshall 2011) . Continuing to deliver high-quality teaching and research require universities and research institutions to find additional income streams while improving efficiency (Etzkowitz & Goktepe-Hulten 2010) . Establishing a spinoff company is a way how to accelerate commercialisation in the stage where the concept was already proofed. It creates a possibility of potential profit for the institution where the commercialised intellectual property originated from. Since the time of the pioneering spinoff firm Genentech was created in the year 1976, the number of companies reached 2,330 in Western Europe and 1,991 in USA in the year 2006 (Table 1) (Hodgson 2006) .
Trend shows their constant growth, Europe including (Enzing et al. 2008 ). An overage European company is younger and smaller that an overage company from USA, probably due to worse access to available investment capital (Table 2) . Nevertheless, one third of these companies undertook healthcare-related activities and a further third provided technical, manufacturing or research services. The remaining 11% of companies were either involved in activities leading to applications in agriculture, food technology, and the environment or Table 1 . Statistical data collected from dedicated biotechnology companies (Hodgson 2006 in the development and manufacturing of biologicallybased diagnostics, largely for the diagnosis of human diseases ( Fig. 1) . Fig. 1 . Breakdown of European biotechnology companies by sector. One third of these companies took root in healthcare-related activities, and a further third provided technical, manufacturing or research services (financial, legal, public relations, technology transfer, consultancy, or other services of a general business nature). The remaining small third of European companies was either involved in activities leading to applications in agriculture, food technology, and the environment (agbio and environment -11% companies) or in the development and manufacturing of biologically-based diagnostics, largely for the diagnosis of human disease (18% companies) (Hodgson 2006) .
Although in the transition of their economies, market demand for new innovative bioscience-based or biotechnology-based companies in the Central Europe is noticeable. New biotechnology companies in Europe are continually mapped by the European Commission, except others. The BioPolis Report, the inventory and analysis of national public policies that stimulate biotechnology research, observed more or less the same national specialisation patterns in biotechnology throughout Europe (Enzing 2007) . The main factor of new innovative companies' success is the ability to rapidly identify the latest research findings from academia and turn them into marketable products (Nilsson 2001 ). However, it should be noted that the management, the science and intellectual property surrounding a biotechnology must all be the highest quality to interest the venture community; if any of these are seriously lacking, the biotechnology is effectively worthless (Stewart et al. 2001) .
The highest concentration of biology-oriented scientific research in Slovakia is in the area of the capital city of Bratislava (Ukropcova & Sturdik 2010 
Methodology
In the initial phase, the project researched the European region of Bratislava for any commercialisation activities. The main objective was to become involved with scientists who have already experienced some industry partnerships, the establishment of a company in Slovakia or international experience outside the Slovak Republic. In the next step the project identified researchers with entrepreneurial talent and ambitions to become bio-entrepreneurs (Moses & Cape 1999) . Their ideas were formulated into business ideas and evaluated (Kolchinsky 2004; Friedman 2006) . The project recognizes the importance of a specific approach to earlystage life sciences valuations (Mayhew 2009 ). The assessment of the innovation is particularly important at the premature stage where there might not be a product or technology.
Not all identified business ideas achieved the required stage of maturity to objectively calculate and estimate economical parameters of the net present value and riskadjusted net present value (Stewart et al. 2001 ). In our research, we adopted a broader perspective in which valuation is considered not as a narrow quantitative process, but as a complex and comprehensive platform. Therefore, the internal diligence represented analysis of product/s, technology, services; market and competition; management and partnership; intellectual property and science, with reasonable certainty and accuracy. Some of the evaluated scientific teams were trained face-to-face in bio-entrepreneurship and introduced to the local funds (Ukropcova & Sturdik 2011) .
In this chapter we describe general findings of the commercialisation research project at first. After presenting technology transfer data in the researched region of Bratislava, we narrow down the results to existing spin-off firms, partnership and intellectual property. Our research mapped laboratory teams with inventors willing to commercialize their research results, earned attention among scientists and a large interest in participation. A large and detailed database of all possible life sciences R&D institutions as a source of commercial potential was created. However, not all of them fulfilled the criteria for biotechnology commercialization, especially as regards the freedom to operate, research proficiency and intellectual property protection. Therefore the project management carefully considered the scientific team that would participate in the project and receive publicly funded support. Identified business ideas were broken down and analyzed. The analyses included two approaches: diligence (internal and external) and categorisation into four stages of business development (Table 3) . Rigorous analyses lead to identification of the right strategic partner who is best positioned to exploit the technology in the early stage of development. Consequently, only the best thirty-two biotechnology research ideas with commercial potential were submitted to a project valuation committee composed of twenty-one university professors, scientists, businessmen and R&D managers from the local biotechnology community. The ideas are listed in chronological order and they represent various biotechnology sectors. More than seventy face-to-face meetings with a single scientist were planned, but the project management trained and coached twice as many people as anticipated. As expected, the R&D institutions including universities and institutes of the Slovak Academy of Science showed a rich pool of research results ready to be analyzed for technology transfer potential. Universities participated in the extent of nine ideas and the Slovak Academy of Science was engaged in the project with nineteen ideas. Four business ideas came from already established private companies and entrepreneurs. Commercial ideas were analyzed towards the stage of potential spin-off development and timing (Fig. 2) . Most of the ideas were prematurely identified as commercial, and were named pre-commercial research. It meant that the scientific team returned to the laboratory before offering the business plan for private investment funds. The stage of business development stood on the other side of our project valuation criteria, where five scientific teams with a commercial value existed as highly probable to be economically exploitable. After forming their business executive summaries, they were forwarded to potential local investors.
Business idea identification in life sciences research and development can be difficult to be testified. Our research identified five valuable business ideas what reached the stage of business development as they included clinical studies or pre-production stage in their research. Almost half of the researched business ideas were analyzed as potential spinoff companies from sector of medical biotechnology (Fig. 3) . As the food industry has a long history in Slovakia, 19% of business ideas originated from the sector of food and feed biotechnology. Surprisingly, the least ideas belonged to environmental biotechnology followed by only 3% from industrial biotechnology. It may be explained by contractual research as a predominant form of technology transfer within this particular sector. Fig. 2 . Valuation of selected business ideas and four stages of potential business development. Half of the commercial inputs were identified as pre-commercial, and therefore not persuasive enough for a private investor. The second level (proof of the concept) was reached by four scientific teams. The third level of evaluation (technology development) was obtained by seven business ideas, whereas the highest level (business development) by five business ideas. Fig. 3 . Sector distribution of the identified biotechnology business ideas. Almost half of the researched business ideas were analyzed as potential spin-off companies from sector of medical biotechnology. 19% of business ideas originated from the sector of food and feed biotechnology. The lowest number of ideas belonged to environmental biotechnology, followed by only 3% from industrial biotechnology. 
Findings
Spin-off creation is a form of transferring commercialisable scientific data to the market. If a researcher provides enough scientific evidence to persuade an investor, venture capitalist appoints managers to cooperate with the selected scientific team. The relationship between managers and researchers is often characterised by asymmetric information to the benefit of the researchers. This asymmetry supposes the setting up of management practices which incite researchers to optimise the company's interests, but this can only be done at the expense of management control. In R&D activities, the informational asymmetry in agency relationship can be overcome by incentive managerial practices. The incentive is strong for the researcher both to reveal his/her information and to obtain financial value from his/her research. Implementing this incentive contract means putting into place certain managerial and organisational practices designed to accompany the researcher-entrepreneur (training, incubator, venture-capital structure, etc.) (Ferrary 2008) . In our research, we did not find any major obstacles in manager-researcher communication; however, a lack of highly-trained technology transfer specialists is an obvious barrier. Finding the right time to transfer a project from academia to industry is critical. Entrepreneurial scientists and venture capitalists may be tempted to do that too soon. The earlier the transfer, the more of the product's final value the company can retain for itself, but the greater the risk that it will fail at the expense of the start-up's investors. At the time of our research, three spin-off companies were successfully established by researchers in the Bratislava region (Table 4) . Coaching and consulting lead to the creation of another three new enterprises as a consequential project impact, even after project implementation ended. All the above-mentioned spin-off companies started running their R&D through the use of regional public funding. Additionally, many of them were granted a larger financial support from the Structural Funds of European Union. The enterprise AB Projekt is engaged in innovative food and drinks technologies, and further, in optimization of oil extraction and ω-3 fatty acid concentrates. Biomedox specialises on human diagnostics, e.g., markers of oxidative stress in saliva. The youngest firm Boimagi develops originally designed drug candidate inhibitors in the field of cancer research. The firm Biorealis focuses on development of biosensors for food biotechnology. Geneton runs except others prenatal and prognostic genetic testing. Scientica aims at novel products in human diagnostics and therapeutics, e.g., larval therapy. The spin-off company STU Vital pursues research in functional foods and obesity prevention products.
Partnership
It is suggested that innovations coming from universities and research institutions stimulate economies by spurring product development, by creating new industries, and by contributing to employment and wealth creation. For this reason, research institutions and universities have come to be highly valued in terms of the economic potential of their research efforts (O'Shea et al. 2008 ). Often they create partnership with the new industry. In our study case, most of evaluated spinoffs considered a long-term quality partnership with the point of origin. The presence of such solid partner would not only be an invaluable R&D partner but a strong reasoning in private financing round. The ability in creating partnership is also an important indicator of market maturity for venture capital funds.
Some consider the rate of commercialisation of R&D inventions to be too low. A premise of this study is that the slow rate of commercialization of university inventions may be due to the lack of adequately trained staff and inventions processing capacity in offices of technology transfer (Swamidass & Vulasa 2008) . Further, high-tech inventions are difficult to market because there are often no ready markets for them, especially if the inventor had no pre-invention contacts with a potential licensee. High-tech inventions originating from public research laboratories may need market space identification, new market creation, and the translation of the laboratory result into an "investor friendly" business plan. In our presented study cases, the researchers introduced the research to a private company at the very early stage and they become partners in product development phase (Table 5) .
It is important to devote greater attention to the study of entrepreneurship in technology transfer in the light of greater government attention, the growth in the phenomenon, the need to identify how wealth can be created from spin-outs, changes in the cultures of universities and differences with technological entrepreneurship in general (Wright et al. 2004 ). The academic entrepreneurs recognize opportunities and shape their ideas to meet the market. The nature of internal research environments, processes and resources and the nature of the scientific discipline may have implications for the process of creation and development of spinoff ventures. In the researched study cases, scientists clearly recognised their invention and its commercial power.
Intellectual property
None of the mapped and evaluated research was patented or licensed in the time period of the project implementation process. Afterwards, when Slovak Research and Development Agency granted R&D projects in three calls for small and medium enterprises (SMEs) and newly created spin-off/start-up enterprises, most of them took the chance to protect their products and knowledge. Broad patent portfolio is not necessary for breakthrough but it can be created being already global to protect own growing market share and widen product portfolio. Breaking onto the market also depends on the successful combination of product development and intellectual property, allied partnership, market and business model linking all factors together (Mets et al. 2010 ).
Business plan modelling
Considered research holds undoubtedly notable commercial potential. A model of the choice to commercialise research depends on the amount and type of pre-commercial research performed, on the timing of commercialization by an academic scientist, and on analyzes of the returns and costs of these choices (Lacetera 2009 ). In some cases, all necessary and sufficient conditions are in place for a newly created spin-off to be the vehicle for the commercialization. The suggested business models are mostly product-platform-based.
The scientists' attractiveness of working in a private sector firm or of starting their own business differ considerably according to their academic discipline and the self-reported commercial potential of their research. The ability to take risks, prior work experience in private firms, and personal experience in cooperating with industry lead to a positive attitude towards switching to private sector employment or entrepreneurship (Fritsch & Krabel 2010) . We confirm that in our study case the scientific teams were considerably open to the daring idea of commercialisation. Certainly, the possibility to reflect the scientific results in the business plan and to apply for a private funding in the later stage was attractive and instructive for researchers. Therefore, coaching and training of the scientific team lead to a business plan and a financial forecast of the proposed business model. The first three years were predicted and a breakeven point is shown in Fig. 4 . Using BioBiz T M software programme, our research forecasted that the point at which costs or expenses and revenue are equal, can be expected at the beginning of the fourth year of the potential spin-off's existence. Variable costs are too high to be balanced with sales income before the fourth year. This optimistic model is in agreement with the most of business models and practical experience in biotechnology spin-off development in Europe (Kolchynski 2004; Hodgson 2006) .
Conclusion
Most world R&D institutions are actively involved in commercialisation. Universities transform from the traditional teaching and research leaders into ambitious entrepreneurial universities (Etzkowitz 2004) . Several types of technology transfer organisations within the universities or university regions are established around to motivate and assist scientists to commercialise their research results (Goktepe-Hulten 2010). Technology transfer offers opportunities for drawing new, mostly private, financial resources into science to narrow the gap between research and market. Undoubtedly, the locality of Bratislava is a Central European region rich in biology/biotechnology-oriented science and in life sciences generally. This research proved the hypothesis that there is a valuable commercial potential here. The research project showed that with proper timing and professional support, the intellectual property and knowledge could be transferred either to an existing industrial entity with an absorptive capacity or to a newly established spin-off enterprise. Early stage partnering represents an important component of life sciences business strategy and therefore is highly valued. The creation of young innovative spin-off companies is most likely to increase the presence of venture capital in Central Europe, and consequently, to stir-up growth of biotechnology industry.
